Oxford Cancer Analytics (OXcan) is at the forefront of developing innovative technologies for early cancer detection, primarily through their DEcancer platform. This platform leverages advanced proteomics and artificial intelligence (AI) to create blood tests that can identify cancer biomarkers—specific proteins in the blood that indicate the presence of cancer. By focusing on high-throughput multi-omics, OXcan aims to discover previously unknown biomarkers, significantly enhancing the accuracy of early cancer detection. Their approach integrates advanced mass spectrometry proteomics with tailored machine learning techniques, allowing for robust analysis of complex clinical data and the identification of effective composite biomarkers for cancer management.

The company’s multidisciplinary team combines expertise in cancer research, clinical medicine, and machine learning to address critical challenges in cancer detection. Their proprietary machine learning methods are designed to handle high-dimensional data and class imbalances, ensuring that the analysis of liquid biopsy data is both effective and reliable. OXcan's commitment to transforming cancer management is evident in their focus on creating readily implementable tests that adhere to standard clinical laboratory procedures, ultimately aiming to improve patient outcomes and provide hope to cancer patients and their families worldwide.

United Kingdom

Oxford Cancer Analytics Ltd (OXcan) is on a mission to enable curative cancer treatments through early detection. OXcan's machine learning platform enables minimally invasive and inexpensive cancer screening in high risk populations through analysing cancer materials shed into the blood. OXcan hopes to create a paradigm shift in screening and eventually replacing invasive tissue biopsy and expensive, complex imaging as the current standard of care. It is safer, cheaper, and detects cancers much earlier, when they are still curable.

Oxford Cancer Analytics

Company Details